As data for both agents continues to emerge, how do clinicians choose between semaglutide and tirzepatide for patients?

Get a breakdown in the latest #DiabetesDialogue with @DianaMIsaacs and @Natalie_Bellini: www.hcplive.com/view/diabete...

#Diabetes

Semaglutide 2.4 mg has received approval for MASH.

In April, #DiabetesDialogue recorded a special edition episode on the ESSENCE trial with Dr. Arun Sanyal.

www.hcplive.com/view/diabete...

#Hepatology #LiverTwitter

Check out the latest #DiabetesDialogue where @DianaMIsaacs and @Natalie_Bellini react to topline data from the SURPASS-CVOT trial of tirzepatide.

Learn more: www.hcplive.com/view/diabete...

#T2D #Type2Diabetes

Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases in the latest #DiabetesDialogue!

www.hcplive.com/view/diabete...

Diabetes Dialogue: ADA 2025 Preview In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

The countdown to #ADA2025 is officially on! Get ready with a rundown from the #DiabetesDialogue crew before heading off to Chicago: www.hcplive.com/view...

In this episode of #DiabetesDialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review notable sessions, emerging clinical insights, and advances in diabetes care from #AACE2025.

🔗 www.hcplive.com/view/diabete...

#Diabetes #Endocrinology

Diabetes Dialogue: Tirzepatide vs Semaglutide for Obesity, Understanding SURMOUNT-5 Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.

Discover the latest findings on tirzepatide vs semaglutide for #obesity from SURMOUNT-5 in the latest #DIabetesDIalogue with @dianamisaacs.bsky.social and Natalie Bellini!

Watch now: www.hcplive.com/view...

What does the latest trial on semaglutide 2.4 mg mean for the medical community?

Hear from lead investigator Arun Sanyal, MD, in the latest #DiabetesDialogue

ICYMI: The ESSENCE trial evidenced semaglutide's benefit in MASH.

#DiabetesDialogue breaks down the trial and what it means for patients:

#Hepatology

In the latest #DiabetesDialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the topline results from the ACHIEVE-1 trial evaluating oral orforglipron for adults with type 2 diabetes inadequately controlled by diet and exercise.

🔗 www.hcplive.com/view/diabete...

#Diabetes

The latest #DiabetesDialogue takes a deep dive into 2 studies from #ACC25, hear from @DianaMIsaacs and @Natalie_Bellini on how these impact decision-making in clinical practice: www.hcplive.com/view/diabete...

Check out the latest #DiabetesDialogue with @DIanaMIsaacs and @Natalie_Bellini as they break down a pair of studies from #ACC25!

Diabetes Dialogue: SOUL and STRIDE Trials from ACC 2025 In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Our latest #DiabetesDialogue tackles the results of SOUL and STRIDE from #ACC25.

Learn more: www.hcplive.com/view...

Diabetes Dialogue: SOUL and STRIDE Trials from ACC 2025 In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

The latest episode of #DiabetesDialogue tackles updates on semaglutide from the STRIDE and SOUL trials at #ACC25.

Listen as Dr. Bellini discusses semaglutide's benefit on walking distance in patients with type 2 diabetes and PAD.

www.hcplive.com/view...

Diabetes Dialogue: Omnipod 5 and Medtronic 780G for Type 2 Diabetes In this episode, hosts offer perspective on recent studies assessing insulin delivery systems in adults with type 2 diabetes.

Discover how the Omnipod 5 simplifies insulin management with meal presets & A1C data insights in the latest #DiabetesDialogue with Drs. Diana Isaacs and Natalie Bellini now:

#DiabetesCare #Type2Diabetes

www.hcplive.com/view...

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics In this episode, hosts explore the latest updates to the ADA Standards of Care on therapeutic innovations and their real-world impact on diabetes management.

In this episode of #DiabetesDialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP, explore the updated @AmDiabetesAssn 2025 Standards of Care, focusing on therapeutic innovations and the impact on diabetes management. #DiabetesCare #Podcasts

🔗 www.hcplive.com/view/diabete...

Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas In this episode, hosts discuss optimizing insulin therapy for people with diabetes using AI-driven algorithms with Eran Atlas, CEO of DreaMed Diabetes.

In the latest episode of #DiabetesDialogue, hosts explore the optimization of insulin therapy using AI-driven algorithms with Eran Atlas, CEO of @DreaMedDiabetes.
🔗 www.hcplive.com/view/diabete...